In this analysis, the age group of 7 < 12 mo was used as the referent group because about one-quarter of infants ≤ 6 mo of age had IgG antibodies against T. gondii in their sera that were most likely acquired in utero.
Bilateral IJVVI was found in 11% of migraine patients without differences between the study groups (16% of MO, 4% of MA) and 16% of the control group (p = 0.85, p = 0.59, p = 0.25).
Using a cut-off value of a combined level of 140 mg/L all patients could be stratified into the correct group of < 14 mo and > 18 mo (Fig. 4a).
Differently, in our cases, MA did not increase the risk of epilepsy compared to MO and the prevalence of epilepsy was similar across the two groups of migraineurs (MO 5.4%, MA 5.8%).
Quantitative variables in each group of migraine patients (MO and MTA) were expressed as medians.
We conducted a systematic literature review to identify cohort studies that sought to quantify diarrhea incidence among any age group of children 0-59 mofof age.
As shown in figure 5 and 6, in comparison to the control group, the expression of Mos was up-regulated in TGA 25 and 125 µg/ml, however, out of our anticipation, it was down-regulated in TGA 5 µg/ml treatment.
In the first group, 17 (20%) patients suffered of MO before the transplant, 15 (18%) MO post transplant, without statistical significance (McNemar's χ2P = 0.79).
Finally, the group of patients suffering from MO that persisted after transplantation (n = 10) showed no relevant change in the pattern of attacks in either frequency or intensity.
Also, the incidence of fever > 38.5°C in the HibMenCY-TT and Hib-OMP groups was consistent with the incidence of fever ≥ 38.9°C reported in a study in which a group of children aged 12 to 23 mo received MMR and VAR alone.
